| http://www.w3.org/ns/prov#value | - MENLO PARK, Calif., April 22, 2014 /PRNewswire/ -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing.
|
